The Pharmalot View

By  Ed Silverman
PHrMA GoBold
The Pharmalot View

Drug industry ad campaign may be too late to save its reputation

By Ed Silverman

Donald Trump
The Pharmalot View

Trump is considering a radical to lead FDA. That’s dangerous for public health

By Ed Silverman

Trump Pharma Industry
The Pharmalot View

Trump should be good medicine for the pharmaceutical industry. Here’s why

By Ed Silverman

The Pharmalot View

Pharma may have defeated Prop 61, but state battles over pricing will continue

By Ed Silverman

Proposition 61 - pharmalot
The Pharmalot View

Californians can sock it to ‘greedy’ pharma. But will ballot vote bring down drug prices?

By Ed Silverman

The Pharmalot View

Health officials should reject latest gambit by EpiPen maker to feed at the public trough

By Ed Silverman

Heather Bresch
The Pharmalot View

Behind the grandstanding, Congress may have taken a key step to clarifying drug prices

By Ed Silverman

Brent Saunders
The Pharmalot View

Allergan CEO looks smart for pledging to rein in prices. But will it make a difference?

By Ed Silverman

IV Chemo
The Pharmalot View

The secretive system for vetting cancer drug use needs an urgent overhaul

By Ed Silverman

Heather Bresch
The Pharmalot View

An open letter to Mylan CEO Heather Bresch about EpiPen pricing

By Ed Silverman

Peter Shumlin
The Pharmalot View

Laws to shed light on drug pricing strategies probably won’t work

By Ed Silverman

Medical Textbook
The Pharmalot View

Pharma should not be allowed a loophole for reporting financial ties to docs

By Ed Silverman

Pharmacy Benefit Managers
The Pharmalot View

The ‘gouge factor’: Big companies want transparency in drug price negotiations

By Ed Silverman

Rising drug cost
The Pharmalot View

Pharma trade group says price gougers are outliers, but then accepts two more

By Ed Silverman

Pfizer
The Pharmalot View

Pfizer wins big in opioid deal with Chicago. But what does the city get?

By Ed Silverman

Aspen FDA
The Pharmalot View

Independence would be good for the FDA and the public

By Ed Silverman

Drug Industry Overstates Patents
The Pharmalot View

Drug industry overstates impact of patent reviews on innovation

By Ed Silverman

Novartis Colombia
The Pharmalot View

Novartis, Colombia face off over cancer drug cost

By Ed Silverman

DNA Money
The Pharmalot View

To get over sticker shock, new payment models are needed for gene therapies

By Ed Silverman

Antibiotics Pharmacy
The Pharmalot View

Cash prizes for pharma are needed to fight superbugs

By Ed Silverman

Lamar Alexander
The Pharmalot View

Why we shouldn’t trade a weakened FDA for more medical research funds

By Ed Silverman

Cash back
The Pharmalot View

Big drug maker presses for money-back guarantee that its science will work

By Ed Silverman

Drug Take Back
The Pharmalot View

Who should pay for disposing unused drugs? Pharma says: not us

By Ed Silverman

Generic medication
The Pharmalot View

Generic drug labels don’t always list known side effects. It’s time to change that

By Ed Silverman

Steven Pearson drug prices
The Pharmalot View

This nonprofit is playing a valuable role in framing the drug price discussion

By Ed Silverman

The Pharmalot View

What Valeant’s fall from grace can teach the drug industry

By Ed Silverman

Pills drug pricing
The Pharmalot View

How much should that drug cost? Depends what disease it treats

By Ed Silverman

Syringes
The Pharmalot View

Obama’s Medicare drug payment overhaul is unproven. But it’s worth a shot

By Ed Silverman

Medication
The Pharmalot View

Could financing health care like a home hold down drug costs?

By Ed Silverman

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy